{"name":"AsclepiX Therapeutics, Inc.","slug":"asclepix-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AXT107 Low Dose","genericName":"AXT107 Low Dose","slug":"axt107-low-dose","indication":"Other","status":"phase_1"},{"name":"AXT107 High Dose","genericName":"AXT107 High Dose","slug":"axt107-high-dose","indication":"Other","status":"phase_1"},{"name":"AXT107 Mid Dose","genericName":"AXT107 Mid Dose","slug":"axt107-mid-dose","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AXT107 Low Dose","genericName":"AXT107 Low Dose","slug":"axt107-low-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AXT107 High Dose","genericName":"AXT107 High Dose","slug":"axt107-high-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AXT107 Mid Dose","genericName":"AXT107 Mid Dose","slug":"axt107-mid-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZkpoOHZJTjRkbXVuWFhqZXVEMWM0b2pzaHQ3dTFZQWFQR3YxUVVzLU8ya2JEbEhKVjEtenMwb20xSDNfRE1tMTd0Qlg0bGROVmdyVURTQjM0STg3Q195aC1zVjJSbnFlR3FOd29PTm8ybGNGWGpkTFd0WERhek1scDEtc1JmUDdkVWxGendmd1Nnbklv?oc=5","date":"2026-03-12","type":"regulatory","source":"openPR.com","summary":"Diabetic Macular Edema Treatment Pipeline Shows Strong - openPR.com","headline":"Diabetic Macular Edema Treatment Pipeline Shows Strong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOLTZUMnVZWlNkS2dkWnlXTFNBd3JkTGdWYmU0S0dkMFd6a3pheS02cy0tdVB3X25WT1FoS0NQMjZVSkFTZXF1QnpVZFllb1FEVkJqWUExTDRfYWFDOFp1eGJzUVNYV19RZk1QdnJIVzZMWi1nakg2X19PandDdkE4V0s0akFMcGdBT21QYzJndWZhNVBjM2drNHlXekU0Tjc3SHFEVjdWY2NYeHV6?oc=5","date":"2025-07-16","type":"pipeline","source":"BioBuzz","summary":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem - BioBuzz","headline":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQTRFblotODlULUo0eHkzR0FDaGlvcnFBYjY1OWlIWEhueERJYVA2LXR5b1hxZUVPWlk4V1plMV80Y3BfcF9RSEVkRGNOV0FINmg4bTY5Z2lTaEVncS1XT2RubFplZm81ZndnUmZVbDlJRHVZaWRUTDBhTFpBU3J5M1NEZFRQMHNaZnYzMkNQeXBleXI3Y29PbXY4dHZRbTV0SWxLYTd4T2EyTWF2aGQ5aU1rdkNiamlFTGdpeGVUZEoxOGhsLURzbTFpbmxzallZREJrdXhSN0M3SXo3UXVhT1dMWk5ZdmhER1E?oc=5","date":"2025-04-30","type":"regulatory","source":"PR Newswire","summary":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight - PR Newswire","headline":"Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vQUExMERQMElsRkhiNTVxSE1yWDc0aWFmM0tKQ0Z3eEVEVEJNUnhjdEdDNk9rUjJhSkxUMnFGUlFaM0d6ZUdubERxWkFYLUZjWm9VaWtvR1NMVHctR0NZ?oc=5","date":"2025-01-13","type":"trial","source":"Nature","summary":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial | Eye - Nature","headline":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related mac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNR2Y0TlE1Z1BFcWxZT3ZyUkc1TFY4ZVBVVjlqN0kxMElOTllSb3FoTmFKZ0FTcmJ6bWg2QVY5SWhlSUNXY2hrWHprU003VUJITUNkR1FMTmJfcWN6TmhQRkU0UXhuc1NUWmVxbmJ2TlZpaXJBemhMcERCd1lEUE56LXpOelhXMGk5ME5zQUE3OVlUUVpaTXpsZFQ2eU9uZlgwcG9heVJtalhxUnlOckdGLUZxZ3VsOVY1NFd3N2otWlJneDRXZ2NJeG02bWp5MF9xejJZ?oc=5","date":"2025-01-07","type":"pipeline","source":"The Chronicle-Journal","summary":"Harrow Appoints Amir H. Shojaei as Chief Scientific Officer - The Chronicle-Journal","headline":"Harrow Appoints Amir H. Shojaei as Chief Scientific Officer - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNVU5hLTJ4cE1hcnh5RDlIdHVwcGlFbzVYai1nZFdCd19LRTZwUGw4Nm5WdkthTU9xdWZ3aHI5LWdUQ1ZZdDJNOEp2NUFBeGZxNGJ2cm11dFU0VDQyLVRSS0p0Z1RyOEZlUUtpMktFVjd1WlVsOG9lX2phTDVmUF9fa2NQTnZaZXdHR05xTmNXVU1pWnU2blVldmM4U2RKZUpzY1ZxblZwNW9GX2tNc2dtVFpRY2I3WVU3MWk3Snlsc3dVT2NMUWJ3empsRm96bVZMbjRNVEg4YVJxekYxSU02R0ZRek1ZeVUzM2lfOGl4S1NNMGF1eFJoMDhDWHB2YlR3aE12T2ozb2JaQVV2ZHVGVQ?oc=5","date":"2024-08-13","type":"pipeline","source":"PR Newswire","summary":"Spencer Trask & Co. Launches Dry Eye Venture Signal12 with Former Aerie Pharmaceutical Executives Thomas Mitro and Marvin Garrett - PR Newswire","headline":"Spencer Trask & Co. Launches Dry Eye Venture Signal12 with Former Aerie Pharmaceutical Executives Thomas Mitro and Marvi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQOE15M0tfMGZYTlFpRzkyUS13eGZQb05nMEFPTTA4bXdlbnNZbmtVdUFSNXV1MDF2VlhSMnFBM2MyVm9aemRGTl9kaTdROGE4T3RqanJWbjNaQTBjaXFsLVJOQVZrY1BJLTFCRHNad2FWcUNUbXlXaXFKVV9ydmhGQ0lickZCODk1Mzk5NHdpNjlfWmpMUlZJQTZpVTRhckU2TFIwZ29Ob3daNTgzbXd0R1VNTlRuR0h5Tkx3RFI3WW9ZamlZTUNFaWhRNVJValQ4Uk9fUg?oc=5","date":"2023-07-27","type":"trial","source":"Ophthalmology Times","summary":"AsclepiX Therapeutics raises $10 million to advance Phase 1/2a clinical study of AXT107 for wet AMD - Ophthalmology Times","headline":"AsclepiX Therapeutics raises $10 million to advance Phase 1/2a clinical study of AXT107 for wet AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxQUTZTejVPLVFSb2VwWDVFdWtVNlUxandNRWlYZ2M2aW9ocnc5UTlRbDlMejZVQ2VDcjZPalV4YzZaRUZQOTA3SFRYeDZ1NmFWWW02Zkxpbk9hNGtYQkR1empadlpZUFh5UkM4Q2VhVXVHQ0VLTGNsdDU2Nk1VMHQtZHFpLUtDRTlmSEpJdFRFV01sLTRlUlg5bWx1Q3ZDZXBrY2FKNVpENTVsNHNQbkVpM2w2dkliOGlzU3NpejljUzFtTFI2QXA0YkZiVWdMaGp1bkE3a3F3c0ptaGNBVkpYRnRfUEdTNjVQNVdHYlF1a1JvN1p5VWZvdXd6TmpiUWV4Z0hINVBzODczSDR3NWNrMjktWHF2OHlKckVVcjA5WTQwLVFYa3l1TlRMdUJBRE11Y0ZpX25IRDVxNl9w?oc=5","date":"2021-10-14","type":"pipeline","source":"Business Wire","summary":"Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics - Business Wire","headline":"Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Ne","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNdEhXVEkta1BCYU9PNnFjbVhJNUhkckdsU1I5cUtHSmxqd0lQalpoZmFfbkxFS3Q4cWZoWVEwQ296SFV4anBZMmJ1VzdDOUdVaWY4d3VHT0J1NG1HeFlIeHBOV2tXeDV2MFVFY0liMG9pZ1BRUEpEclR5Z00tV1RsamFB?oc=5","date":"2021-04-13","type":"pipeline","source":"I95 Business","summary":"Women Leaders in Life Sciences - I95 Business","headline":"Women Leaders in Life Sciences - I95 Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNRlEybzFtNkxWem1nTUo2WUFaYTMtX243bW9MQVVCb2xCM01wODR4Q0VjdTBnQWJnaHFBdV9MOTdpQk1WSUVUbUtCQVpYWUhGd1J6NkJaMmVnUzNoZ2pRcEpFemNOY0RJZ0NBbDJ0d1BpQmxQang0TUdaOEJ1RFR1Y1k2dUlNX3k5Mlhka2FoSmhSRzIzZGFpdElvUTg5bG5ybU1hbEdmS2tIYTEzYlBreVdJbEFJaW1GelZTTHQxWFBteW96?oc=5","date":"2020-05-04","type":"pipeline","source":"PR Newswire","summary":"Rapha Capital Management Leads Series A Financing for FIZE Medical Inc. - PR Newswire","headline":"Rapha Capital Management Leads Series A Financing for FIZE Medical Inc.","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}